Legend Biotech Medical Affairs

Applications are now open for Legend Biotech’s inaugural ELITE Program (Emerging Leadership & Innovation in Cell Therapy Excellence). The annual grant initiative is designed to recognize and support early-career healthcare professionals advancing novel cell therapy approaches for the treatment of multiple myeloma. Through the ELITE Program, we’re investing in the next generation of innovators and the ideas that can help advance research, education, and care for patients living with multiple myeloma. Applications are open through November 20, 2026. Learn more and apply: bit.ly/4wnt47v

New data is coming at #IMS26. At the 23rd International @Myeloma_Society Annual Meeting in Glasgow, Legend Biotech will present data from our CAR-T cell therapy, including long-term, post-authorization and real-world findings. These insights build on learnings from our clinical program as we continue our focus on advancing scientific innovation and reaching patients globally. Learn more about the data we’ll be sharing in Glasgow: bit.ly/4xITIZj #LegendBiotech #CellTherapy #ClinicalResearch

What is CAR-T cell therapy? This personalized approach uses a patient’s own T cells to help fight cancer. Learn how it works and why continued innovation matters for people living with blood cancers. #CellTherapy #PatientsFirst #Oncology #Biotech

#LegendNews: At @EHA_Hematology, we presented Phase 1 data for LB2501, our investigational in vivo CD19/CD20 dual-targeting CAR-T therapy. Results showed clinical activity after a single infusion and a favorable safety profile to date. Read more: bit.ly/4erUIIR

#LegendNews at #EHA2026. We’ll present initial Phase 1 LB2501 data in relapsed/refractory B-cell NHL in a late-breaking oral presentation. The abstract highlights encouraging clinical activity and a favorable safety profile. Learn more: bit.ly/4o6cjKS @EHA_Hematology

We’re at the @ASCO Annual Meeting this week. 👋 Attending? Swing by booth #21955 to learn more about how we’re advancing cell therapy in multiple myeloma and beyond. Also, check out our Heroes in Practice display honoring community oncologists. #ASCO26 #CART #CellTherapy

At #ASCO26, we’re bringing together members of the oncology community for an evening of conversation around the future of cell therapy, innovation, and what’s next in oncology. 📅 May 30 🕕 6:30-9:30 PM CT For more information, contact your local MSL. bit.ly/4vetpIN

#ASCO26 starts this week. We’ll be sharing new data across our CAR-T portfolio, including investigational findings in solid tumors and new analyses in multiple myeloma. Stop by booth #21955 if you’re attending. #CellTherapy

#LegendNews: Early LB2102 data in solid tumors will be presented at #ASCO26. Additional data presented at @ASCO reinforce established efficacy and safety profile in #MultipleMyeloma. Come find us at ASCO Booth #21955 to learn more and read more at: bit.ly/4f16QCG

Advancing #PatientCare is a team effort. This week at #ONS2026, the Legend team is connecting with #Oncology nurses and care teams to share perspectives, learn from each other, and support the delivery of advanced therapies. Stop by and visit our booth #1103 to learn more.

#LegendNews: Research highlighting our investigational solid tumor CAR-T and continued evidence generation in multiple myeloma from our #CellTherapy portfolio will be presented at @ASCO. Attending #ASCO26? Visit booth #29155 to say hello! #ASCO26 #Biotech #CancerResearch

Our VP & Head of Early-Stage Drug Dev, Dong Geng, will participate in a panel on in vivo cell therapy Feb. 11 @ 1:20 p.m. at #IO360Summit. 📍 Track 2: Cell Therapy Plenary 🎤 In Vivo Cell Therapy: Rewriting the Rules of Cell-Based Treatment io360summit.com/

We will present data on our #CART #CellTherapy for #MultipleMyeloma at #Tandem26 Meetings of @ASTCT and @CIBMTR in Salt Lake City. Six posters will highlight efficacy, safety, and real-world outcomes, supporting earlier use in the treatment journey. investors.legendbiotech.com/…

An updated CARTITUDE-4 analysis published in @TheLancetOncol reports outcomes evaluating earlier use of our #CART #CellTherapy for #MultipleMyeloma, adding to the growing clinical evidence informing treatment decisions and future research. 🔗 thelancet.com/journals/lanon…

This week, we’re in Boston for the CAR-TCR Summit 2025! 🕐 9/24 8:20 am: Fireside Chat w/ Mythili Koneru 🕐 9/24 5:30 pm: Claudin 18.2 & DLL3 Targeted CAR-T Cells for GC & SCLC 🕐 9/25 1:45 pm: Advancing cell therapy w/ Ben Oshrine Driving the future of #CART #CellTherapies!

We’re thrilled to be at the @Myeloma_Society Annual Meeting in Toronto! Stop by booth #427 to meet our team & learn about our portfolio of #CellTherapies. Hope to see you at #IMS25! #Toronto2025